Mirum Pharmaceuticals, Inc. (MIRM) Q2 2019 Earnings Results

Mirum Pharmaceutical Misses on EPS, Stock Down 4.38%

Mirum Pharmaceutical's earnings report showed a significant loss per share, which contributed to a 4.38% drop in stock price. The lack of revenue figures and guidance suggests uncertainty about the company's financial outlook. Investors may be concerned about the ongoing challenges mentioned by management, which could impact future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-5.31	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed caution regarding the current market conditions. They did not provide specific guidance or revenue expectations.

Management did not provide specific revenue figures or guidance for future quarters.

The company acknowledged ongoing challenges in the market.

Mirum Pharmaceutical Misses on EPS, Stock Down 4.38%

Key numbers

Management commentary

Mirum Pharmaceuticals, Inc.

More earnings this week

Mirum Pharmaceutical Misses on EPS, Stock Down 4.38%

Key numbers

Management commentary